RU2014145440A - Офтальмологическая система-носитель для лекарственных средств, офтальмологический набор, а также применение офтальмологической композиции - Google Patents

Офтальмологическая система-носитель для лекарственных средств, офтальмологический набор, а также применение офтальмологической композиции Download PDF

Info

Publication number
RU2014145440A
RU2014145440A RU2014145440A RU2014145440A RU2014145440A RU 2014145440 A RU2014145440 A RU 2014145440A RU 2014145440 A RU2014145440 A RU 2014145440A RU 2014145440 A RU2014145440 A RU 2014145440A RU 2014145440 A RU2014145440 A RU 2014145440A
Authority
RU
Russia
Prior art keywords
weight
ophthalmic
oil
carrier system
group
Prior art date
Application number
RU2014145440A
Other languages
English (en)
Russian (ru)
Inventor
Уте ШТАЙНФЕЛЬД
Франк ХОЛЬЦЕР
Хек Хи ЛИ
Маркус МАХЛЕР
Original Assignee
Ф. Хольцер Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хольцер Гмбх filed Critical Ф. Хольцер Гмбх
Publication of RU2014145440A publication Critical patent/RU2014145440A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
RU2014145440A 2012-05-15 2013-05-14 Офтальмологическая система-носитель для лекарственных средств, офтальмологический набор, а также применение офтальмологической композиции RU2014145440A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168139.9 2012-05-15
EP12168139.9A EP2664329A1 (de) 2012-05-15 2012-05-15 Ophthalmologisches Vehikelsystem
PCT/EP2013/059927 WO2013171204A2 (de) 2012-05-15 2013-05-14 Ophthalmologisches vehikelsystem für arzneistoffe, ophthalmologisches kit sowie verwendung einer ophthalmologischen zusammensetzung

Publications (1)

Publication Number Publication Date
RU2014145440A true RU2014145440A (ru) 2016-07-10

Family

ID=48463974

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014145440A RU2014145440A (ru) 2012-05-15 2013-05-14 Офтальмологическая система-носитель для лекарственных средств, офтальмологический набор, а также применение офтальмологической композиции

Country Status (12)

Country Link
US (1) US20150139973A1 (enExample)
EP (2) EP2664329A1 (enExample)
JP (1) JP2015521182A (enExample)
KR (1) KR20150014966A (enExample)
CN (1) CN104394859A (enExample)
AU (1) AU2013261873A1 (enExample)
CA (1) CA2873265A1 (enExample)
HK (1) HK1202427A1 (enExample)
IN (1) IN2014DN09594A (enExample)
MX (1) MX2014013884A (enExample)
RU (1) RU2014145440A (enExample)
WO (1) WO2013171204A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666836T3 (es) * 2014-06-04 2018-05-08 Alfasigma S.P.A. Formulaciones homogéneas que comprenden ácidos grasos poliinsaturados omega-3 (n-3 PUFA) y resveratrol para administración oral
US10240112B2 (en) * 2014-06-06 2019-03-26 Archer Daniels Midland Company Microemulsions and their use in metal working fluids, wood stains, or wood sealers
PL3203989T3 (pl) 2014-10-09 2020-06-29 Distretto Tecnologico Sicilia Micro E Nano Sistemi S.C.A.R.L. Nanostrukturalne preparaty do dostarczania sylibininy i innych składników czynnych do leczenia chorób oczu
CA2973471A1 (en) 2015-01-12 2016-07-21 Kedalion Therapeutics, Inc. Micro-droplet delivery device and methods
KR20170135862A (ko) 2015-04-10 2017-12-08 켄달리온 테라퓨틱스 인코포레이티드 교체 가능한 앰플을 갖는 압전 디스펜서
JP6760275B2 (ja) * 2015-05-12 2020-09-23 ライオン株式会社 眼科用組成物
WO2017025471A1 (en) * 2015-08-07 2017-02-16 Gene Signal International Sa Sterile emulsion comprising a stable phosphorothioate oligonucleotide
EP3128007A1 (en) * 2015-08-07 2017-02-08 Gene Signal International SA Sterile emulsion comprising a stable phosphorothioate oligonucleotide
WO2017075055A1 (en) 2015-10-26 2017-05-04 President And Fellows Of Harvard College Reduced and oxidized polysaccharides and methods of use thereof
WO2018077958A1 (en) 2016-10-27 2018-05-03 Unilever N.V. A personal care composition comprising curcuminoids
JP6134853B1 (ja) * 2016-10-28 2017-05-24 参天製薬株式会社 エピナスチン含有点眼液
EP3570986B1 (en) 2017-01-20 2025-03-19 Bausch + Lomb Ireland Limited Piezoelectric fluid dispenser
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
JP6635974B2 (ja) * 2017-04-24 2020-01-29 参天製薬株式会社 エピナスチン含有点眼液
CN107158020A (zh) * 2017-05-18 2017-09-15 德施普科技发展温州有限公司 一种眼科用药物组合物及其制备方法
KR102867583B1 (ko) 2017-12-08 2025-10-13 보슈 롬 아일랜드 리미티드 유체 전달 정렬 시스템
KR102094882B1 (ko) * 2017-12-21 2020-04-28 주식회사 유엠아이옵틱스 항균 누점 플러그 및 그 제조방법
EP3773651A4 (en) * 2018-04-04 2022-02-16 Eye Co Pty Ltd. Low thc hemp extract and method of treatment or prevention of an eye disease
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
US20190314197A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
DE102018208110A1 (de) 2018-05-23 2019-11-28 F. Holzer Gmbh Abgabekopf und Abgabevorrichtung zur dosierten Abgabe flüssiger Präparate sowie Verwendungsmöglichkeiten
CA3102410A1 (en) 2018-07-03 2020-01-09 Kedalion Therapeutics, Inc. Topical ocular delivery devices and methods for using the same
WO2020047197A1 (en) * 2018-08-29 2020-03-05 Ocugen, Inc. Ophthalmic compositions and methods of use
WO2020070751A1 (en) * 2018-10-03 2020-04-09 Tathagata Dutta Semisolid dosage forms for ophthalmic delivery of antioxidants
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
DE112020002226T5 (de) * 2019-05-03 2022-01-20 Mark Lobanoff Nahinfrarot-Beleuchtung für chirurgische Verfahren
EP3982930A1 (en) * 2019-06-11 2022-04-20 SIFI S.p.A. Microemulsion compositions
CN110384584A (zh) * 2019-06-28 2019-10-29 四川省一直牛健康管理有限公司 一款中西方芳香植物配伍的功能性眼罩及其制备方法
WO2021049864A1 (ko) * 2019-09-11 2021-03-18 (주) 메드빌 두릅나무 추출물을 함유하는 안구건조증 개선용 조성물
US12496218B1 (en) 2019-11-12 2025-12-16 Bausch + Lomb Ireland Limited Fractionated topical ocular drug delivery methods and devices for use in the same
JP6736752B2 (ja) * 2019-12-17 2020-08-05 参天製薬株式会社 エピナスチン含有点眼液
CN111269161B (zh) * 2019-12-26 2022-03-08 深圳市真兴生物医药研究中心有限公司 厚朴酚与萝卜硫素拼接物及其制备方法和应用
KR20230004480A (ko) * 2020-03-13 2023-01-06 퍼스트-맥네스 컴퍼니 영양성 및 항 바이러스 특성을 갖는 기타 이점을 제공하는 조성물 및 방법
EP4120974A4 (en) 2020-04-17 2024-05-22 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
WO2021212038A1 (en) 2020-04-17 2021-10-21 Kedalion Therapeutics, Inc. Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
EP3919047A1 (en) * 2020-06-03 2021-12-08 AZAD Pharma AG Microemulsion for the treatment of dry eye syndrome
US20230226002A1 (en) * 2020-06-15 2023-07-20 University Of Utah Research Foundation Retinal bioavailbility of synthetic very-long-chain polyunsaturated fatty acids
JP2020169213A (ja) * 2020-07-15 2020-10-15 参天製薬株式会社 エピナスチン含有点眼液
WO2022018605A1 (en) * 2020-07-19 2022-01-27 Narayana Nethralaya Foundation A formulation of combination of genistein and calcitriol for management of inflammatory ocular surface conditions
US11033516B1 (en) * 2020-09-18 2021-06-15 Spring Discovery, Inc. Combination therapies with disulfiram
TW202228659A (zh) * 2020-09-25 2022-08-01 日商伊德姆有限公司 乾眼症之預防劑、改善劑及治療劑
IT202000026236A1 (it) * 2020-11-04 2022-05-04 Iromed Group S R L Composizione oftalmica
IL314467A (en) * 2022-01-26 2024-09-01 Amarin Pharmaceuticals Ie Ltd Lymphatic releasing fatty acid preparations and their uses for lymphatic inclusion and treatment of systemic disease
CN116253891B (zh) * 2022-08-22 2024-09-20 中南大学湘雅医院 Chta-dsb-da高分子载体及其载药纳米材料的制备和在眼科药物中的应用
KR102513994B1 (ko) * 2022-10-26 2023-03-24 김태윤 반려동물의 눈물 착색예방용 조성물
CN116196263A (zh) * 2023-02-23 2023-06-02 河南大学 一种含有干细胞提取物的护肤组合物及其制备方法
CN118477012B (zh) * 2024-05-07 2025-01-21 广州品域美妆创新科技有限公司 一种含胶原的抗皱紧致组合物及其在化妆品中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98747A0 (en) * 1991-07-05 1992-07-15 Yissum Res Dev Co Ophthalmic compositions
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
CA2146006C (en) * 1993-08-18 2004-10-12 Louis Desantis, Jr. Use of ergoline derivatives for the treatment of glaucoma
US20100173876A1 (en) * 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
EP1466668B1 (en) 2003-04-09 2006-01-18 URSAPHARM Arzneimittel GmbH & Co. KG Fluid dispenser
EA016221B1 (ru) * 2006-03-31 2012-03-30 ВИСТЭКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи Офтальмические композиции и способ лечения аллергических заболеваний глаз
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
US10201548B2 (en) * 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
KR101656121B1 (ko) * 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
DE102010050570A1 (de) * 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors

Also Published As

Publication number Publication date
IN2014DN09594A (enExample) 2015-07-31
EP2664329A1 (de) 2013-11-20
US20150139973A1 (en) 2015-05-21
WO2013171204A3 (de) 2014-01-09
JP2015521182A (ja) 2015-07-27
AU2013261873A1 (en) 2014-12-04
CA2873265A1 (en) 2013-11-21
MX2014013884A (es) 2015-06-23
WO2013171204A2 (de) 2013-11-21
CN104394859A (zh) 2015-03-04
KR20150014966A (ko) 2015-02-09
EP2849741A2 (de) 2015-03-25
HK1202427A1 (zh) 2015-10-02

Similar Documents

Publication Publication Date Title
RU2014145440A (ru) Офтальмологическая система-носитель для лекарственных средств, офтальмологический набор, а также применение офтальмологической композиции
US20240350425A1 (en) Compositions comprising mixtures of semifluorinated alkanes
CA3142049C (en) Semifluorinated alkane compositions
WO2013171203A1 (de) Fluidspender enthaltend eine ophthalmologische zusammensetzung
EP2635266A1 (de) Zusammensetzung und arzneimittel enthaltend omega-3-fettsäuren sowie einen modulator
MX2012010684A (es) Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
CA3173219A1 (en) Ophthalmic formulation and its use
Mastrota Newly approved Miebo holds power for treatment of dry eye disease
HK1233187A1 (en) Compositions comprising mixtures of semifluorinated alkanes
HK1210041B (en) Compositions comprising mixtures of semifluorinated alkanes

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20171017